Esperion Therapeutics, Inc. (ESPR)
| Previous close | 1.7300 |
| Open | 1.7000 |
| Bid | 1.6500 x 100 |
| Ask | 1.7300 x 100 |
| Day's range | 1.6400 - 1.7300 |
| 52-week range | 0.7000 - 3.4000 |
| Volume | |
| Avg. volume | 6,235,340 |
| Market cap | 333.386M |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8500 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.59 |
ZacksWhy Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireEsperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately
- GlobeNewswire
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – – Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers – – NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revasculari
